SageView Advisory Group LLC Acquires 464 Shares of Zoetis Inc. (NYSE:ZTS)

SageView Advisory Group LLC increased its stake in Zoetis Inc. (NYSE:ZTS) by 9.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,553 shares of the company’s stock after purchasing an additional 464 shares during the quarter. SageView Advisory Group LLC’s holdings in Zoetis were worth $1,063,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its position in Zoetis by 31.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Wellington Management Group LLP boosted its stake in Zoetis by 2.5% in the third quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock worth $2,147,730,000 after buying an additional 297,044 shares in the last quarter. Capital World Investors raised its stake in shares of Zoetis by 0.6% during the fourth quarter. Capital World Investors now owns 9,064,158 shares of the company’s stock worth $1,788,988,000 after acquiring an additional 57,798 shares in the last quarter. Northern Trust Corp raised its position in Zoetis by 3.3% in the 3rd quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock worth $1,068,804,000 after purchasing an additional 196,771 shares during the period. Finally, Norges Bank bought a new stake in shares of Zoetis in the 4th quarter valued at about $980,646,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the transaction, the executive vice president now owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ZTS. HSBC cut their target price on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Piper Sandler restated an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Barclays reduced their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. Finally, Stifel Nicolaus dropped their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $211.75.

Zoetis Stock Down 0.4 %

Shares of Zoetis stock opened at $170.55 on Monday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm has a market cap of $77.82 billion, a price-to-earnings ratio of 32.86, a PEG ratio of 2.65 and a beta of 0.89. The company has a 50-day moving average of $165.75 and a 200 day moving average of $179.54. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The business had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same quarter last year, the firm earned $1.31 earnings per share. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 1.01%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is 33.33%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.